Related Experiment Videos
Kasabach-Merrit syndrome in infants
1Department of Pediatric Surgery, Karadeniz Technical University, Faculty of Medicine, Trabzon, Turkey.
Panminerva Medica
|August 5, 1998
Summary
Interferon alfa-2a and compression effectively treated Kasabach-Merrit syndrome in infants with large hemangiomas and severe thrombocytopenia. This therapy led to significant lesion regression or complete excision in most cases.
Area of Science:
- Pediatric Oncology
- Dermatology
- Hematology
Background:
- Kasabach-Merritt syndrome (KMS) is a rare condition characterized by large hemangiomas, severe thrombocytopenia, and coagulopathy.
- Infants with KMS often present with life-threatening complications, necessitating effective treatment strategies.
Purpose of the Study:
- To evaluate the efficacy of interferon alfa-2a and compression in treating infants diagnosed with Kasabach-Merritt syndrome.
Main Methods:
- Four infants with KMS and extensive cutaneous hemangiomas were treated at a university hospital.
- Treatment involved intensive care, antibiotics, blood products, and for three patients, interferon alfa-2a with compression.
- Previous treatments with steroids were unsuccessful in two patients.
Main Results:
- Three patients treated with interferon alfa-2a and compression showed positive outcomes.
- Two patients experienced 60-80% regression of hemangioma lesions after five months of therapy.
- One patient achieved complete excision of the hemangioma lesion after one month of treatment.
Conclusions:
- Interferon alfa-2a combined with compression demonstrates remarkable effectiveness in managing Kasabach-Merritt syndrome.
- This therapeutic approach offers a promising alternative for infants suffering from this rare condition.